Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
Allarity Therapeutics (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company, has appointed Jeff Ervin as its new Chief Financial Officer. Ervin, who brings nearly 20 years of executive leadership experience, succeeds Alexander Epshinsky. He previously served as Co-CFO at NYSE-listed DayDayCook and CEO of NASDAQ-listed IMAC Holdings.
Ervin holds an MBA from Vanderbilt University and will initially join Allarity in a half-time capacity, with potential for full-time employment based on company needs. The company is focused on developing stenoparib, a dual PARP and WNT pathway inhibitor, as a personalized cancer treatment using its proprietary DRP® patient selection technology.
Allarity Therapeutics (NASDAQ: ALLR), una società farmaceutica in fase clinica di fase 2, ha nominato Jeff Ervin come nuovo Chief Financial Officer. Ervin, che porta con sé quasi 20 anni di esperienza nella leadership esecutiva, succede ad Alexander Epshinsky. In precedenza, ha ricoperto il ruolo di Co-CFO presso DayDayCook, quotata al NYSE, e CEO di IMAC Holdings, quotata al NASDAQ.
Ervin è in possesso di un MBA conseguito presso la Vanderbilt University e inizialmente entrerà in Allarity con un impegno part-time, con la possibilità di passare a tempo pieno in base alle esigenze dell’azienda. La società è focalizzata sullo sviluppo di stenoparib, un inibitore duale delle vie PARP e WNT, come trattamento personalizzato per il cancro utilizzando la sua tecnologia proprietaria di selezione pazienti DRP®.
Allarity Therapeutics (NASDAQ: ALLR), una compañía farmacéutica en etapa clínica de fase 2, ha nombrado a Jeff Ervin como su nuevo Director Financiero. Ervin, quien aporta casi 20 años de experiencia en liderazgo ejecutivo, sucede a Alexander Epshinsky. Anteriormente, fue Co-CFO en DayDayCook, listado en NYSE, y CEO de IMAC Holdings, listado en NASDAQ.
Ervin posee un MBA de la Universidad de Vanderbilt y se unirá inicialmente a Allarity en un puesto de medio tiempo, con posibilidad de pasar a tiempo completo según las necesidades de la empresa. La compañía se centra en el desarrollo de stenoparib, un inhibidor dual de las vías PARP y WNT, como tratamiento personalizado contra el cáncer utilizando su tecnología propietaria de selección de pacientes DRP®.
Allarity Therapeutics (NASDAQ: ALLR)는 2상 임상 단계의 제약회사로, Jeff Ervin을 새로운 최고재무책임자(CFO)로 임명했습니다. Ervin은 약 20년간의 경영 리더십 경험을 보유하고 있으며, Alexander Epshinsky의 후임입니다. 그는 이전에 NYSE 상장사 DayDayCook에서 공동 CFO를, NASDAQ 상장사 IMAC Holdings에서 CEO를 역임했습니다.
Ervin은 Vanderbilt 대학교에서 MBA를 취득했으며, 처음에는 파트타임으로 Allarity에 합류할 예정이며 회사의 필요에 따라 정규직 전환 가능성이 있습니다. 회사는 독자적인 DRP® 환자 선별 기술을 활용해 PARP 및 WNT 경로를 동시에 억제하는 이중 억제제인 stenoparib을 맞춤형 암 치료제로 개발하는 데 주력하고 있습니다.
Allarity Therapeutics (NASDAQ : ALLR), une société pharmaceutique en phase clinique 2, a nommé Jeff Ervin en tant que nouveau Directeur Financier. Ervin, qui apporte près de 20 ans d’expérience en leadership exécutif, succède à Alexander Epshinsky. Il a précédemment été Co-CFO chez DayDayCook, coté au NYSE, et CEO chez IMAC Holdings, coté au NASDAQ.
Ervin est titulaire d’un MBA de l’Université Vanderbilt et rejoindra initialement Allarity à temps partiel, avec une possibilité de passer à temps plein selon les besoins de l’entreprise. La société se concentre sur le développement de stenoparib, un inhibiteur double des voies PARP et WNT, comme traitement personnalisé du cancer utilisant sa technologie propriétaire de sélection des patients DRP®.
Allarity Therapeutics (NASDAQ: ALLR), ein Pharmaunternehmen in der klinischen Phase 2, hat Jeff Ervin als neuen Chief Financial Officer ernannt. Ervin bringt fast 20 Jahre Führungserfahrung mit und folgt auf Alexander Epshinsky. Zuvor war er Co-CFO bei DayDayCook, einem an der NYSE gelisteten Unternehmen, und CEO von IMAC Holdings, das an der NASDAQ notiert ist.
Ervin besitzt einen MBA von der Vanderbilt University und wird zunächst in Teilzeit bei Allarity starten, mit der Möglichkeit einer Vollzeitbeschäftigung je nach Unternehmensbedarf. Das Unternehmen konzentriert sich auf die Entwicklung von Stenoparib, einem dualen PARP- und WNT-Signalweg-Inhibitor, als personalisierte Krebstherapie unter Verwendung der firmeneigenen DRP®-Patientenauswahltechnologie.
- Appointment of experienced CFO with public company leadership background
- New CFO's proven track record in successful public listings and national expansion
- Half-time employment structure demonstrates focus on operational efficiency
- Part-time CFO arrangement might indicate financial constraints
- Departure of previous CFO could signal potential transition challenges
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology, today announced the appointment of Jeff Ervin as the Company’s new Chief Financial Officer (CFO). He succeeds Alexander Epshinsky, who will remain engaged with the Company during a transition period.
Mr. Ervin brings nearly two decades of executive leadership experience across the healthcare, biotech, and other sectors. He most recently served as Co-Chief Financial Officer at NYSE-listed DayDayCook and was previously Chief Executive Officer of NASDAQ-listed IMAC Holdings, where he led the company through a successful public listing and national expansion. Earlier in his career, he held a senior finance role at Medx Publishing. Mr. Ervin currently serves on the board of directors of NASDAQ-listed Cingulate Inc., a biopharmaceutical company focused on the development of new product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
“We are pleased to welcome Jeff to the Allarity executive team. His strong track record in public company leadership and financial management aligns well with our mission to accelerate the clinical development of stenoparib,” said Thomas Jensen, Chief Executive Officer of Allarity Therapeutics. “Jeff’s extensive experience will be highly valuable in supporting a sustainable financial strategy and the execution of our expanding clinical trial activities. I would also like to extend my sincere thanks to Alex for his valuable contributions to Allarity and wish him continued success in his future endeavors.”
Mr. Ervin holds an MBA in Finance and Strategy from Vanderbilt University’s Owen Graduate School of Management, a BS in Finance from Miami University, and has completed continuing education courses in corporate and internet strategy at Stanford University. He has entered into an employment agreement for half-time employment with Allarity, with full-time employment to be considered periodically based on the Company’s needs, a structure that reflects the Company’s continued focus on operational and financial efficiency.
About Stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company’s current expectations or forecasts of future events. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected contributions of Mr. Ervin as Chief Financial Officer; the Company’s ability to maintain financial flexibility; and its continued advancement of stenoparib through clinical development. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s ability to execute its financial and clinical development plans; uncertainties associated with clinical trial timelines and outcomes; regulatory requirements and approvals; and general market and operational risks. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our Form 10-K annual report filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, available at the SEC’s website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
investorrelations@allarity.com
Media Contact:
Thomas Pedersen
Carrotize PR & Communications
+45 6062 9390
tsp@carrotize.com
Attachment
FAQ
Who is the new CFO of Allarity Therapeutics (NASDAQ: ALLR)?
What is Jeff Ervin's previous experience before joining Allarity Therapeutics?
What is Allarity Therapeutics' main product in development?
What is the employment arrangement for Allarity's new CFO?
Who did Jeff Ervin replace as CFO at Allarity Therapeutics?
